Navigation Links
K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants
Date:8/3/2010

adverse effect, if any, on its revenue, assets and liquidity and capital resources, as more fully described in Note 20 – "Subsequent Events" of the Notes to the Consolidated Financial Statements in the Form 10-Q;
  • changes in the current and future business environment, including interest rates and capital and consumer spending;
  • the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized;
  • the possibility of not obtaining FDA approvals or delay in obtaining FDA approvals, including with respect to Gestiva™, as well as the number of preterm births for which Gestiva™ may be prescribed, its safety profile and side effects profile;
  • acceptance of and demand for the Company's new pharmaceutical products or current products upon their return to the marketplace;
  • the introduction and impact of competitive products and pricing, including as a result of so-called authorized generic drugs;
  • new product development and launch, including the possibility that any product launch may be delayed;
  • reliance on key strategic acquisitions;
  • the availability of raw materials and/or products manufactured for the Company under contract manufacturing agreements with third parties;
  • the regulatory environment, including regulatory agency and judicial actions and changes in applicable laws or regulations;
  • fluctuations in revenues;
  • the difficulty of predicting international regulatory approvals, including timing;
  • the difficulty of predicting the pattern of inventory movements by the Company's customers;
  • the impact of competitive response to the Company's sales, marketing and strategic efforts, including introduction or potential introduction of generic or competing products against products sold by the Company and its subsidiaries;
  • risks that the Company may not ultimately prevail in litigation, including product li
    '/>"/>

  • SOURCE K-V Pharmaceutical Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
    2. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
    3. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
    4. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
    5. China BCT Further Expands its Footprint by Opening 12 New Retail Pharmaceutical Stores
    6. Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program
    7. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
    8. Viscira Delivers Key Presentation to Pharmaceutical Marketing Professionals at Leading Digital Industry Conference
    9. Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
    10. United Therapeutics and Lees Pharmaceutical Sign Remodulin Distribution Agreement for China
    11. Angiotech Pharmaceuticals Announces Conference Call and Webcast
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... Davis, California (PRWEB) January 22, 2015 ... of Accelerator Mass Spectrometry (AMS) services to the pharmaceutical ... PhD has joined the company in the position of ... 30 years of broad and valuable experience in drug ...
    (Date:1/22/2015)... RBJ today announces the firm brokered a long-term lease totaling ... biopharmaceutical company, at Two Ledgemont Center in Lexington, ... president, and Brian Cohen , senior vice president, represented ... 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
    (Date:1/22/2015)... RBJ today announces the firm brokered a long-term lease totaling ... biopharmaceutical company, at Two Ledgemont Center in Lexington, ... president, and Brian Cohen , senior vice president, represented ... 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
    (Date:1/22/2015)... The laboratory information management systems market ... number of technological advancements due to factors such as ... to integrate healthcare systems, and increasing government support for ... integration. Key players in the market focus on technological ...
    Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4
    ... quarter of 2008 versus third quarter ... ... CRY ),a biomaterials, medical device and tissue processing company, announced,today that revenues ... to $22.2 million in the third quarter of 2007.,Excluding orthopaedic tissue processing ...
    ... Oct. 30 Human Genome,Sciences, Inc. (Nasdaq: HGSI ... to discuss its financial results for the quarter ended,September ... on Thursday,November 6, 2008, after the capital markets close., ... call will be hosted by senior management and will ...
    ... Pharmaceuticals,Inc. (Nasdaq: VNDA ), a biopharmaceutical company ... candidates for central,nervous system disorders, today announced financial ... 30, 2008., Vanda reported research and development ... $3.8 million, compared to $5.5 million in the ...
    Cached Biology Technology:CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 2CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 3CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 4CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 5CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 6CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 7CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 8CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 9CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 10CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007 11Human Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2008 Financial Results 2Vanda Pharmaceuticals Reports Third Quarter 2008 Results 2Vanda Pharmaceuticals Reports Third Quarter 2008 Results 3Vanda Pharmaceuticals Reports Third Quarter 2008 Results 4Vanda Pharmaceuticals Reports Third Quarter 2008 Results 5Vanda Pharmaceuticals Reports Third Quarter 2008 Results 6Vanda Pharmaceuticals Reports Third Quarter 2008 Results 7Vanda Pharmaceuticals Reports Third Quarter 2008 Results 8Vanda Pharmaceuticals Reports Third Quarter 2008 Results 9Vanda Pharmaceuticals Reports Third Quarter 2008 Results 10
    (Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced the ... report to their offering. ... in this market is the increasing demand for medical ... of patient data for quick and correct diagnosis during ...
    (Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in India ... One major trend emerging in this market is the ... more than one characteristic of an individual for verification ...
    (Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ...
    Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
    ... is easy: we call it fire. But ... oxygen to a particular carbon atom in a complicated ... to an enzyme called cytochrome P450. Because cytochrome P450 ... been called "nature,s blowtorch," and its job is analogous ...
    ... issue of GEOSPHERE, published by the Geological Society ... interest include common ground in the disagreement between ... a USGS Great Basin Paleontological Database filled with ... terrestrial laser scanners and digital cameras in three-dimensional ...
    ... (EMBL) in Heidelberg, Germany, and the EMBL-European Bioinformatics Institute ... how sex chromosomes are regulated. A chromatin modifying enzyme ... one copy of the sex chromosome X, while females ... sex chromosomes in fruit flies and binds to different ...
    Cached Biology News:A molecular switch turns on the flame in 'nature's blowtorch' 2June GEOSPHERE media highlights 2June GEOSPHERE media highlights 3June GEOSPHERE media highlights 4X chromosome exposed 2
    ... sensitive laser confocal systems designed for rapid ... that meet your expectations, differentiating between a ... the signal on the bottom as well ... for increased sensitivity. Results with VersArray ChipReader ...
    ... one plate. The new ArraySlide 96 chamber ... x 7mm) individual printing surfaces for multiple ... studies. Unlike other systems, this device utilizes ... of contaminating adhesives. The chamber itself is ...
    Bio-Plex Manager software, version 3.0, 5 license netshare, is a five-user software package that provides access to data from the Bio-Plex suspension array system from a server. This version does not...
    ... Hyb-Seal slide chambers are vapor-tight adhesive chambers for ... chambers are affixed over a sample on a ... of two ports, and the ports are then ... removed and replaced to allow exchange of reaction ...
    Biology Products: